Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04493099
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT04487106
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 6
- Registration Number
- NCT04477486
- Locations
- 🇯🇵
Yamagata University Hospital /ID# 221573, Yamagata-shi, Yamagata, Japan
🇯🇵Aichi Cancer Center Hospital /ID# 221565, Nagoya-shi, Aichi, Japan
🇯🇵Okayama University Hospital /ID# 221623, Okayama-shi, Okayama, Japan
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Ospedale Maggiore Di Trieste
- Target Recruit Count
- 15
- Registration Number
- NCT04454580
- Locations
- 🇮🇹
SC Ematologia Ospedale Maggiore, Trieste, Italy
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 40
- Registration Number
- NCT04450173
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04447768
- Locations
- 🇺🇸
Stanford University Medical Center (Data collection only), Stanford, California, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 30
- Registration Number
- NCT04447716
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT04435691
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT04422210
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Emory University, Atlanta, Georgia, United States
🇩🇰Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT04416451
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.